Navigation Links
Using coxibs and NSAIDs to treat osteoarthritis
Date:8/13/2007

Mt Laurel, NJ 13 August 2007 - In an Editorial, to be published in the international journal Osteoarthritis and Cartilage (http://intl.elsevierhealth.com/journals/joca/), published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in treating osteoarthritis (OA). The Editorial summarizes the outcomes of an international workshop organized by the Osteoarthritis Research Society International (OARSI) and the International COX-2 Study Group, held 2425 March 2007. The authors urge that an evidence-based approach must be taken when making recommendations to patients.

OA, the most common form of arthritis, is a major medical problem. It has been estimated that over 20 million Americans are afflicted with OA, and that number will rise to 40 million by the year 2020. Controversy now exists as to the safest and most efficacious way of treating the disease, particularly with respect to use of NSAIDs, both non-selective and selective (so-called COX-2 selective agents or coxibs). Adverse reactions related to the gastrointestinal tract, particularly with the non-selective NSAIDs, have been described; more recently, concerns have been expressed related to the cardiovascular system with both groups of agents.

A recent scientific statement from the American Heart Association (AHA) made recommendations with regard to the treatment of OA.1 A number of these recommendations are challenged in the Editorial2 in Osteoarthritis and Cartilage, with particular concern about their impact on appropriate use of these agents.

The Editorial questions the recommendation made in the AHA statement which described a stepped care approach to pharmacologic therapy for musculoskeletal diseases. The Editorial strongly recommends that several aspects of the AHA statement be reconsidered. For example, it urges that the AHA withdraw their non-evidence-based recommendations that high-dose aspirin be administered alone as a first line therapy for patients with chronic pain and arthritis.

Dr Roland W. Moskowitz, Professor of Medicine at Case Western Reserve University/University Hospitals of Cleveland, lead author of the Editorial comments, "Careful review of the pros and cons of using these agents, and the situations in which they are most safely and effectively used, is required to help us understand how best to take advantage of their availability".

The input by the OARSI/COX-2 International Study Group provides evidence-based background and guidance that will be of help to physicians, and to patients, in the use of these important commonly used agents.


'/>"/>
Contact: Ian Salusbury
ian.salusbury@elsevier.com
44-186-584-3000
Elsevier
Source:Eurekalert

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
3. Researchers urge caution in using ear tube surgery
4. Ulcer causing bug found in stored food
5. Using Stem Cells To Treat Incontinence In Women
6. Flu-Drugs Are Causing Resistance Across The World
7. Researchers at Cornell University as been reported using research fund by false claims
8. Relief to pregnant women using fertility drugs
9. The hazards of using disinfectant hand gel
10. Colon cancer risk linked to genes causing Hemochromatosis
11. Teens Misusing Nicotine-Replacement Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... ... Outreach is a program that strives to better communities around the world by ... community. It also provides the opportunity for team members to become involved in ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently ... Area counties for 2017. Almost 1,000 nominations were submitted and a little over ... Results were announced the magazine’s January 2017 issue . , Under the ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living ... line of activated charcoal products. With more and more people opting to go ... according to how they cater to specific needs. , Moody Zook focused particularly ...
(Date:1/13/2017)... ... 13, 2017 , ... People with type 2 diabetes know ... easy as checking the nutrition label on foods for grams of sugar. But ... sugar-free, proteins can influence — either positively or negatively — insulin secretion and ...
(Date:1/13/2017)... ... , ... With the increasing public preference for chemical-free personal ... alternatives for customers who have grown more conscious about maintaining their health and ... charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s decision ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , Jan. 16, 2017  Cumberland Pharmaceuticals Inc. (NASDAQ: ... Kenneth J. Krogulski , CFA to its Board of ... of Berkshire Asset Management LLC . He is ... independent SEC registered investment advisory firm with over $1.5 ... 37 years, experience in security analysis and portfolio management. ...
(Date:1/14/2017)... Jan. 14, 2017  Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... According ...
(Date:1/13/2017)... January 13, 2017 According ... and Equipment Market by Method (Biochemical (Calcium Phosphate, ... Protein Production), End User - Global Forecast to ... global market from 2016 to 2021. This market ... 2021 from USD 715.4 Million in 2016, at ...
Breaking Medicine Technology: